Personalized rifampin dosing guided by a urine test

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-site, randomized Phase 1 trial at Haydom Lutheran Hospital in northern Tanzania uses urine spectrophotometry to approximate rifampin exposure and compares early versus delayed urine-guided dose adjustment. Participants provide timed urine and serum samples across the 24-hour dosing interval with serum later measured by gold-standard mass spectrometry to confirm exposures. Those with below-target urine rifampin excretion receive incremental dose increases and repeat sampling, and stool samples are collected to study enteropathogen burden and its effect on absorption. The primary efficacy endpoint is the proportion reaching predefined serum AUC0-24 targets by Day 21, and the primary safety endpoint is the number of severe adverse events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 3 or older
2. Diagnosed with active, rifampin-susceptible, pulmonary TB- sputum positive for M. tuberculosis complex without rpoB mutation, or culture for M. tuberculosis with conventional rifampin susceptibility OR among children unable to expectorate, meeting confirmed or probable consensus clinical case definitions for intrathoracic childhood TB
3. Initiating combination anti-TB therapy with isoniazid, rifampin, pyrazinamide, and ethambutol
4. Subject or guardian is able to provide informed consent; and for children 7 years or older, provide assent
5. Stated willingness to comply with all trial procedures and availability for the duration of the trial
6. Resident within a pre-defined geographic area to ensure TB clinic follow-up

Exclusion Criteria:

1. Urinary incontinence: may complicate urine collection
2. Oliguria: may complicate urine collection and limit correlation of urinary excretion and serum concentrations
3. Kidney disease, defined as a glomerular filtration rate (GFR) \< 60 mL/min: In 5R01 AI137080, those adults with GFR \< 60 mL/min had reduced correlation or urinary rifampin excretion and serum concentrations.
4. Severe anemia, defined as a hemoglobin level less than 7 g/dL: given planned phlebotomy
5. Elevated liver function tests, defined as DAIDS grade 3 or above (ALT or AST \>/= 5 x upper limit of normal): may confound potential toxicity signals of dose adjustment strategy
6. Pregnancy: Urine rifampin spectrophotometry has not been studied in pregnant people, higher dose rifampin also less studied in pregnancy, and may confound potential toxicity signals (e.g. elevated liver function tests in pregnancy). Urine pregnancy test will be completed at screening in people of child-bearing potential. Child-bearing potential is defined as a person able to menstruate (menstruation in the last 12 months) and not receiving a form of contraception with less than \<1% failure rate (oral levonorgestrel, IUD or etonogestrel implant).
7. Weight \<10.0 kg (dose increase may exceed 30mg/kg/dose)
8. Current treatment with a drug known to have significant interaction with anti-TB therapy
9. Excessive alcohol use? (for example, Men consuming \> 14 standardized drinks per week and/or \> 4 drinks per day OR women consuming \>7 standardized drinks per week, and/or \>3 drinks per day, or at the discretion of the investigator(s).

Where it's running

• Haydom Lutheran Hospital
  Haydom, Tanzania Recruiting

Study contacts

• Study coordinator: Scott Heysell, MD, MPH
• Email: skh8r@uvahealth.org
• Phone: 4342439064

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Doxycycline added to standard treatment for central nervous system tuberculosis

  This trial tests whether adding doxycycline to standard anti‑TB therapy and corticosteroids helps adults with central nervous system tuberculosis live longer or have less severe neurological disability.

  Recruiting at 5 sites Phase 2 National University Hospital, Singapore · Medan, Medan and 5 other locations · NCT06446245

• Biomarker Test for Diagnosis and Monitoring of Extrapulmonary Tuberculosis

  This study tests biomarker-based methods to help diagnose extrapulmonary TB and monitor treatment in adults, including people living with HIV, using samples from affected sites in Kenya.

  Recruiting at 2 sites Nagasaki University · Nairobi and 1 other locations · NCT07901387

• Short-Course TB Treatment for Children with Non-Severe Pulmonary TB

  This trial tests two shorter-treatment options for kids with non-severe pulmonary TB to see if they can clear the infection as well as the standard 6-month plan.

  Recruiting at 13 sites Phase 2 Huashan Hospital · Fuzhou, Fujian and 12 other locations · NCT07893444

• Combined oral contraceptive timing with Ganfeborole in healthy women

  This study tests how the contraceptive Microgynon behaves in the body when given alone and with Ganfeborole in healthy women who can’t get pregnant.

  Recruiting Phase 1 GlaxoSmithKline · Madrid · NCT07784894

• Isoniazid inhalation in TB patients: a first-in-human look at local tolerability and body levels

  This early study tests inhaled isoniazid to see how well it tolerates the lungs and how it behaves in the body in adults with tuberculosis.

  Recruiting Phase 1 University Medical Center Groningen · Groningen · NCT07708779

• How the immune system responds to mycobacterial infections

  This study tests how the immune system changes in people with tuberculosis and related mycobacterial infections.

  Recruiting First Affiliated Hospital of Ningbo University · Ningbo · NCT07638670

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.